Novel Formulation of Carbidopa/Levodopa Under Review for Parkinson Disease
The NDA is supported by data from the phase 3 RISE-PD trial.
Parkinson Disease
ENT-01 Safe, Improves Constipation in Patients With Parkinson Disease
Improvement seen in weekly complete spontaneous bowel movement rate and in secondary end points
FDA Needs More Data Before Deciding on Apomorphine Infusion Device
SPN-830 provides a continuous subutaneous infusion of apomorphine through an infusion pump
Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease
Two studies show lack of benefit in primary or secondary end points with cinpanemab or prasinezumab versus placebo
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
NDA Submitted for Continuous SC Infusion Therapy for Parkinson Disease
ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion.
First Generic Version of Apokyn Drug Cartridges Gets FDA Approval
The approval is only for the drug cartridges, which are compatible for use with the Apokyn Pen, the brand name pen injector.
Supernus One Step Closer to Decision on Apomorphine Infusion Device
SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump.
Functionally Scored Carbidopa/Levodopa Tablet Now Available for Parkinson Disease
The FDA approved Dhivy in November 2021 based upon bioavailability studies comparing Dhivy to an immediate-release tablet containing 25mg of carbidopa and 100mg of levodopa.
